How much revenue does Exact Sciences make?

Exact Sciences reported $3.25 billion in revenue for fiscal year 2025, up 17.7% from $2.76 billion in fiscal year 2024.

Where does Exact Sciences make most of its revenue?

United States: 93% of revenue by region in fiscal year 2025, followed by Outside of United States (7%).

What companies are similar to Exact Sciences?

Listed companies of a similar size in the same industry (DNA testing equipment) include Genesystem Co., Ltd. (363250.KQ), GeneMatrix Inc. (109820.KQ), Guardant Health, Inc. (GH), Celestra Inc. (352770.KQ).

Exact Sciences Corporation (EXAS) Stock

FinancialsSegmentsShareholders

About Exact Sciences Corporation

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Sc...

At a glance

Exact Sciences reported revenue of $3.25 billion for fiscal year 2025, up 17.7% from fiscal year 2024, and net income of -$207.95 million. United States was its largest region in fiscal year 2025, with 93% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.